180 related articles for article (PubMed ID: 33483721)
1. Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload.
Lambert M; Mendes-Ferreira P; Ghigna MR; LeRibeuz H; Adão R; Boet A; Capuano V; Rucker-Martin C; Brás-Silva C; Quarck R; Domergue V; Vachiéry JL; Humbert M; Perros F; Montani D; Antigny F
Cardiovasc Res; 2021 Nov; 117(12):2474-2488. PubMed ID: 33483721
[TBL] [Abstract][Full Text] [Related]
2. Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension.
Lambert M; Boet A; Rucker-Martin C; Mendes-Ferreira P; Capuano V; Hatem S; Adão R; Brás-Silva C; Hautefort A; Michel JB; Dorfmuller P; Fadel E; Kotsimbos T; Price L; Jourdon P; Montani D; Humbert M; Perros F; Antigny F
Cardiovasc Res; 2018 May; 114(6):880-893. PubMed ID: 29360952
[TBL] [Abstract][Full Text] [Related]
3. In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression.
Le Ribeuz H; Courboulin A; Ghigna MR; Lambert M; Hautefort A; Humbert M; Montani D; Cohen-Kaminsky S; Perros F; Antigny F
Respir Res; 2020 Jul; 21(1):186. PubMed ID: 32678044
[TBL] [Abstract][Full Text] [Related]
4. Characterization of
Lambert M; Capuano V; Boet A; Tesson L; Bertero T; Nakhleh MK; Remy S; Anegon I; Pechoux C; Hautefort A; Rucker-Martin C; Manoury B; Domergue V; Mercier O; Girerd B; Montani D; Perros F; Humbert M; Antigny F
Circ Res; 2019 Sep; 125(7):678-695. PubMed ID: 31347976
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary vascular mechanical consequences of ischemic heart failure and implications for right ventricular function.
Philip JL; Murphy TM; Schreier DA; Stevens S; Tabima DM; Albrecht M; Frump AL; Hacker TA; Lahm T; Chesler NC
Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1167-H1177. PubMed ID: 30767670
[TBL] [Abstract][Full Text] [Related]
6. Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension.
Antigny F; Hautefort A; Meloche J; Belacel-Ouari M; Manoury B; Rucker-Martin C; Péchoux C; Potus F; Nadeau V; Tremblay E; Ruffenach G; Bourgeois A; Dorfmüller P; Breuils-Bonnet S; Fadel E; Ranchoux B; Jourdon P; Girerd B; Montani D; Provencher S; Bonnet S; Simonneau G; Humbert M; Perros F
Circulation; 2016 Apr; 133(14):1371-85. PubMed ID: 26912814
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Heterozygous
Bohnen MS; Roman-Campos D; Terrenoire C; Jnani J; Sampson KJ; Chung WK; Kass RS
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28889099
[TBL] [Abstract][Full Text] [Related]
8. PM2.5 exposure aggravates left heart failure induced pulmonary hypertension.
Chen JJ; Ma WM; Yuan JL; Cui LQ
Acta Cardiol; 2019 Jun; 74(3):238-244. PubMed ID: 30348056
[No Abstract] [Full Text] [Related]
9. Proteomic Analysis of KCNK3 Loss of Expression Identified Dysregulated Pathways in Pulmonary Vascular Cells.
Le Ribeuz H; Dumont F; Ruellou G; Lambert M; Balliau T; Quatredeniers M; Girerd B; Cohen-Kaminsky S; Mercier O; Yen-Nicolaÿ S; Humbert M; Montani D; Capuano V; Antigny F
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036472
[TBL] [Abstract][Full Text] [Related]
10. Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
Hautefort A; Mendes-Ferreira P; Sabourin J; Manaud G; Bertero T; Rucker-Martin C; Riou M; Adão R; Manoury B; Lambert M; Boet A; Lecerf F; Domergue V; Brás-Silva C; Gomez AM; Montani D; Girerd B; Humbert M; Antigny F; Perros F
Circulation; 2019 Feb; 139(7):932-948. PubMed ID: 30586714
[TBL] [Abstract][Full Text] [Related]
11. Characterization and regulation of wild-type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension.
Cunningham KP; Holden RG; Escribano-Subias PM; Cogolludo A; Veale EL; Mathie A
J Physiol; 2019 Feb; 597(4):1087-1101. PubMed ID: 30365877
[TBL] [Abstract][Full Text] [Related]
12. KCNK3 Mutation Causes Altered Immune Function in Pulmonary Arterial Hypertension Patients and Mouse Models.
West JD; Austin ED; Rizzi EM; Yan L; Tanjore H; Crabtree AL; Moore CS; Muthian G; Carrier EJ; Jacobson DA; Hamid R; Kendall PL; Majka S; Rathinasabapathy A
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065088
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of mesenchymal stem cell delivery via a novel cardiac bioscaffold on right ventricles of pulmonary arterial hypertensive rats.
Schmuck EG; Hacker TA; Schreier DA; Chesler NC; Wang Z
Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1005-H1013. PubMed ID: 30822119
[TBL] [Abstract][Full Text] [Related]
14. Right Ventricular and Right Atrial Function Are Less Compromised in Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction: A Comparison With Pulmonary Arterial Hypertension With Similar Pressure Overload.
van Wezenbeek J; Kianzad A; van de Bovenkamp A; Wessels J; Mouratoglou SA; Braams NJ; Jansen SMA; Meulblok E; Meijboom LJ; Marcus JT; Vonk Noordegraaf A; José Goumans M; Jan Bogaard H; Handoko ML; de Man FS
Circ Heart Fail; 2022 Feb; 15(2):e008726. PubMed ID: 34937392
[TBL] [Abstract][Full Text] [Related]
15. Physiological and pathophysiological roles of the KCNK3 potassium channel in the pulmonary circulation and the heart.
Saint-Martin Willer A; Santos-Gomes J; Adão R; Brás-Silva C; Eyries M; Pérez-Vizcaino F; Capuano V; Montani D; Antigny F
J Physiol; 2023 Sep; 601(17):3717-3737. PubMed ID: 37477289
[TBL] [Abstract][Full Text] [Related]
16. Mechanical stretching of the pulmonary vein mediates pulmonary hypertension due to left heart disease by regulating SAC/MAPK pathway and the expression of IL-6 and TNF-α.
Huang W; Liu H; Pan Y; Yang H; Lin J; Zhang H
J Cardiothorac Surg; 2021 May; 16(1):127. PubMed ID: 33971931
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
[TBL] [Abstract][Full Text] [Related]
18. Excitation-contraction coupling and relaxation alteration in right ventricular remodelling caused by pulmonary arterial hypertension.
Antigny F; Mercier O; Humbert M; Sabourin J
Arch Cardiovasc Dis; 2020 Jan; 113(1):70-84. PubMed ID: 31924541
[TBL] [Abstract][Full Text] [Related]
19. Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension.
Adão R; Mendes-Ferreira P; Santos-Ribeiro D; Maia-Rocha C; Pimentel LD; Monteiro-Pinto C; Mulvaney EP; Reid HM; Kinsella BT; Potus F; Breuils-Bonnet S; Rademaker MT; Provencher S; Bonnet S; Leite-Moreira AF; Brás-Silva C
Cardiovasc Res; 2018 Jul; 114(8):1165-1177. PubMed ID: 29584808
[TBL] [Abstract][Full Text] [Related]
20. A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats.
Sang P; Kucherenko MM; Yao J; Li Q; Simmons S; Kuebler WM; Knosalla C
J Vis Exp; 2022 Mar; (181):. PubMed ID: 35311828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
